All AbMole products are for research use only, cannot be used for human consumption.
Cilomilast (SB-207499) is among the first of a new generation of PDE4 inhibitors (Ki ≈100 nM). Cilomilast (SB-207499)inhibits HPDE4 and LPDE4 catalytic activity with equal potency (Ki ≈100 nM). SB-207499 and rolipram are equipotent against LPDE4, but cilomilast (SB-207499) is 100-fold less potent against HPDE4. This profile suggests that cilomilast (SB-207499) retain the anti-inflammatory activity of rolipram yet have a decreased tendency to produce side effects.
| Cell Experiment | |
|---|---|
| Cell lines | U937 cells |
| Preparation method | Incubating U937 cells (1-2 × 106) at 37 °C in a shaking water bath with Cilomilast for 1 min before the addition of 0.1 μM PGE2 (total volume of 200 μL). The incubation proceeds for an additional 4 min and is stopped by the addition of 0.1 mL of HClO4 (17.5%), neutralized with 0.15 ml of K23 (1.0 M) and diluted to 1 mL with sodium acetate buffer. Centrifuging the samples at 3000 × g for 10 min. Assaying aliquots of the supernatant fraction for cAMP content by radioimmunoassay using commercially available kits. |
| Concentrations | 0.1-10 μM |
| Incubation time | 5 min |
| Animal Experiment | |
|---|---|
| Animal models | Balb/c, CD-1 and C57B1/6 male mice weighing from 18 to 25 g with human monocytes or endotoxin-induced shock |
| Formulation | Olive oil |
| Dosages | 3, 6, 12, 25, 50 mg/kg |
| Administration | Gavage |
| Molecular Weight | 343.42 |
| Formula | C20H25NO4 |
| CAS Number | 153259-65-5 |
| Solubility (25°C) | DMSO 59 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[2] Stephen Rennard, et al. The efficacy and safety of cilomilast in COPD
| Related PDE Products |
|---|
| MR-L2
MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4), activates representative PDE4 long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5). MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC50 of 1.2 μM. |
| MMPX
MMPX is a potent PDE1 inhibitor. |
| T-0156
T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. |
| TPN171
TPN171 is a potent, selective and oral bioavailable inhibitor of phosphodiesterase type 5 (PDE5) with an IC50 of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH). |
| Mesopram
Mesopram (Daxalipram) is an orally active phosphodiesterase (PDE) 4 inhibitor. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
